Results 1 to 10 of about 23,321 (158)

Identification of a Novel, Oncogenic and Targetable <i>TPR::ABL2</i> Fusion Gene in T-Cell Acute Lymphoblastic Leukaemia. [PDF]

EJHaem
ABSTRACT ABL2 rearrangements represent a subtype of acute lymphoblastic leukaemia (ALL) associated with poor prognosis and survival. This study reports a high‐risk T‐cell ALL (T‐ALL) case with a novel TPR::ABL2 gene fusion resulting from a chromosomal deletion.
Lagonik E, Page EC, Eadie LN, Schutz CE, Rehn JA, Heatley SL, Moore AS, Healy M, Whyte M, Hughes TP, Yeung DT, White DL.   +11 more
europepmc   +2 more sources

Dasatinib targets c-Src kinase in cardiotoxicity

Toxicology Reports, 2023
Dasatinib is a multitargeted kinase inhibitor used for treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. Unfortunately, treatment of cancer patients with some kinase inhibitors has been associated with cardiotoxicity.
Manar Elmadani, Sami Raatikainen, Orvokki Mattila, Tarja Alakoski, Jarkko Piuhola, Pirjo Åström, Olli Tenhunen, Johanna Magga, Risto Kerkelä   +8 more
doaj   +1 more source

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia

Respiratory Medicine Case Reports, 2022
Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia.
Go Makimoto, Mahito Misawa, Yoshinobu Maeda, Katsuyuki Kiura   +3 more
doaj   +1 more source

Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling

Frontiers in Cardiovascular Medicine, 2022
Dasatinib treatment is approved as first-line therapy for chronic myeloid leukemia. However, pulmonary hypertension (PH) is a highly morbid and often fatal side-effect of dasatinib, characterized by progressive pulmonary vascular remodeling.
Rui Wang, Rui Wang, Jinjin Pan, Jinzhen Han, Miaomiao Gong, Liang Liu, Yunlong Zhang, Ying Liu, Dingyou Wang, Qing Tang, Na Wu, Lin Wang, Jinsong Yan, Hua Li, Yuhui Yuan   +14 more
doaj   +1 more source

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Haematologica, 2023
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced ...
Patrick Harrington, Richard Dillon, Deepti Radia, Philippe Rousselot, Donal P. McLornan, Mark Ong, Anna Green, Alessandro Verde, Farzana Hussain, Kavita Raj, Shahram Kordasti, Claire Harrison, Hugues de Lavallade   +12 more
doaj   +1 more source

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Frontiers in Oncology, 2023
Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second-line treatment for those who are resistant or intolerant to therapy with imatinib.
Fang Cheng, Fang Cheng, Qiling Xu, Qiling Xu, Qiang Li, Qiang Li, Zheng Cui, Zheng Cui, Weiming Li, Fang Zeng, Fang Zeng   +10 more
doaj   +1 more source

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

Haematologica, 2013
Dasatinib is effective in most chronic phase chronic myeloid leukemia patients both in first-line therapy and following imatinib failure. While imatinib uptake into CD34+ cells is low compared to mononuclear cells, few data evaluate how well dasatinib ...
Devendra K. Hiwase, Verity A. Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes   +5 more
doaj   +1 more source

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review

Therapeutic Advances in Respiratory Disease, 2022
Dasatinib, a tyrosine kinase inhibitor, is usually prescribed for chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. However, some patients may develop an intolerance to this drug over the years.
Sang-A Kim, Byoung Soo Kwon, Jin-Haeng Chung, Ji Yun Lee, Soo-Mee Bang, Jeong-Ok Lee   +5 more
doaj   +1 more source

MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. [PDF]

PLoS ONE, 2013
Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib.
Yanfen Fang, Like Zhong, Meihua Lin, Xinglu Zhou, Hui Jing, Meidan Ying, Peihua Luo, Bo Yang, Qiaojun He   +8 more
doaj   +1 more source

Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Neoplasia: An International Journal for Oncology Research, 2012
Epidermal growth factor receptor (EGFR) is an important oncoprotein that promotes cell growth and proliferation. Dasatinib, a bcr-abl inhibitor, has been approved clinically for the treatment of chronic myeloid leukemia and demonstrated to be effective ...
Yu-Chin Lin, Meng-Hsuan Wu, Tzu-Tang Wei, Shu-Hui Chung, Kuen-Feng Chen, Ann-Lii Cheng, Ching-Chow Chen   +6 more
doaj   +1 more source